Microfluidic Devices Diagnose World’s Return to New Normal - EE Times India
As countries work to contain the Covid-19 pandemic, the need for effective diagnostic testing has been front and center. Accurate, accessible testing is a precondition for the population’s gradual return to normal — or, most likely, a new normal. Yole Développement’s Sébastien Clerc Diagnostics companies have mobilized their resources and readied tens of tests, sometimes […]
As countries work to contain the Covid-19 pandemic, the need for effective diagnostic testing has been front and center. Accurate, accessible testing is a precondition for the population’s gradual return to normal — or, most likely, a new normal.
Diagnostics companies have mobilized their resources and readied tens of tests, sometimes within weeks. In the face of the health emergency, the U.S. Food and Drug Administration and other regulatory bodies have lowered their standards and granted “Emergency Use Authorizations” for some of the tests. Since mid-March, companies including GenMark, BioFire, Cepheid, and Mesa Biotech have received approvals for their microfluidic-based rapid molecular testing for SARS-CoV-2, the pathogen that causes Covid-19. A new dynamic of innovation is emerging around the world, and it seems obvious that there will be a before and after Covid-19.
“The pandemic will certainly leave its mark on the way we work, produce, and live in society,” Sébastien Clerc, technology and market analyst in microfluidics, sensing, and actuating at Yole Développement (Lyon, France), told EE Times Europe. The structure of the diagnostics industry will change as it intensifies its R&D activity and continues to consolidate. Overall, the microfluidics market will grow at a CAGR of 11.7% to US$17.4 billion in 2024, Yole predicts.
